Tiletamine Hcl And Zolazepam Hcl

Verify with FDA CVM →

34 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
34
Total Reports
15
Deaths Reported
4410.0%
Death Rate

Active Ingredients

Tiletamine Hcl And Zolazepam Hcl

Administration Routes

IntramuscularUnknownIntravenousParenteralSubcutaneous

Species Affected

Dog 18
Cat 15
Unknown 1

Most Affected Breeds

Cat (unknown) 9
Dog (unknown) 9
Domestic Shorthair 6
Crossbred Canine/dog 1
Unknown 1
Basenji 1
Shepherd Dog - German 1
Spaniel (unspecified) 1
Poodle - Standard 1
Bulldog 1

Most Reported Reactions

Lack of efficacy - NOS 16
Death by euthanasia 8
Hyperthermia 4
Unrelated death 4
Hypothermia 2
Vomiting 2
Sudden death 2
Death 2
Immediate pain upon injection 2
INEFFECTIVE, EUTHANASIA 1
Mydriasis 1
Neurological signs NOS 1

Outcome Breakdown

Recovered/Normal
12 (36.4%)
Euthanized
11 (33.3%)
Outcome Unknown
5 (15.2%)
Died
4 (12.1%)
Ongoing
1 (3.0%)

Data Summary

Metric Value
Total adverse event reports 34
Reports involving death 15
Case-fatality rate (reported events) 4410.0%
Distinct species in reports 3
Distinct breeds in reports 13
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tiletamine Hcl And Zolazepam Hcl Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 34 adverse event reports referencing Tiletamine Hcl And Zolazepam Hcl, including 15 reports in which the animal died — a 4410.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tiletamine Hcl And Zolazepam Hcl. Reported administration routes include Intramuscular, Unknown, Intravenous, Parenteral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tiletamine Hcl And Zolazepam Hcl reports are Dog (18 reports), Cat (15 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Cat (unknown) (9), Dog (unknown) (9), Domestic Shorthair (6) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tiletamine Hcl And Zolazepam Hcl are Lack of efficacy - NOS (16), Death by euthanasia (8), Hyperthermia (4), Unrelated death (4). Of the 33 reports with a coded outcome, Recovered/Normal is the leading category at 36.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tiletamine Hcl And Zolazepam Hcl.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial